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1. Introduction 
Osteomyelitis is a bone infection that may initiate due to a local trauma or infection or it 
may originate due to infections occurring elsewhere in the body (microorganisms are 
transported by the bloodstream in this case). The bone may be predisposed to infection 
because of trauma or because of a medical condition like diabetes. The microorganisms 
responsible for the infection are usually pyogenic bacteria. The most frequent infectious 
agents are in order of prevalence Staphylococcus aureus, Streptococcus (groups A and B), 
Haemophilus influenzae, and Enterobacter species [1]. 
Osteomyelitis is highly prevalent in patients with diabetes (extremity bones), patients with 
fractured and exposed bones and with bone systems that have continuous internal or 
external trauma/aggression/inflammation (vertebrae in adults). In theory any bone may 
develop the disease. Extremity bones (arms and legs, especially in children) and spine 
(vertebral column, especially in adults) are the most affected. In diabetic patients, a large 
percentage of the patients who have foot ulcers developed osteomyelitis in extremity bones 
(feet and toes) [1].  
Patients with diabetes usually have chronic diseases in the lower ends because they have a 
higher incidence of vascular failure and reduced sensitivity to pain (diabetic neuropathy). 
Consequently, they may have skin lesions called skin ulcers that grow in length and in depth, 
often without the patient realizing it, due to the absence of pain. These ulcers greatly increase 
the chance of other complications, like soft-tissue infection, tissue infection that may culminate 
in osteomyelitis and some sort of amputation due to infection that installs both in soft and 
bone tissues.  It is known that diabetic patients have lower immunity responses than the 
population in general and added with the poor peripheral blood circulation, become more 
vulnerable to infections, which are more difficult to respond to the treatment.  10% of diabetic 
patients will develop some sort of foot ulcers followed by amputation. 85% of amputations are 
preceded by a foot ulcer and 70-100% of the ulcers show signs of peripheral neuropathy 
associated with various degrees of commitment of the peripheral vasculature [2]. 
The mortality rate is usually low, unless sepsis occurs. The severity of the disease increases 
with the dissemination of the infection to surrounding tissues and articular cavity; evolution 
to chronic osteomyelitis, amputation of the involved extremity, generalized infection or 
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sepsis. It is a disease that can only be treated with long-term systemic and local antiobiotics 
treatments [1,3] 
Photodynamic therapy (PDT) is a promising clinical modality for the management of 
various tumors and nonmalignant diseases, due to two main effects that are induced by 
photo-activation of specific drugs called photosensitizers: cell killing properties [4-12] and 
its ability to modulate the immune response [13, 14]. PDT is based on an excited-state 
process called photosensitization (see below), which is a combination of a photosensitizer 
that is selectively localized in the target tissue and illumination of the lesion with visible 
light, resulting in photodamage and subsequent cell death (microbial killing). The first 
time the photodynamic effect shown was in the area of microbiology. Raab conducted in-
vitro experiments showing the killing of paramecium parasites by PDT [15]. Several other 
papers were published showing the photo-induced killing of microorganisns [4]. 
However, development in this area was bunged for several decades because of the 
discovery of penicillin. With the growing problem of bacterial antibiotic resistance in the 
last 15 years, there was a resurge in the research focusing in the anti-microbial application 
of PDT. Currently, PDT is a potential approach to treat localized infectious diseases 
mainly due microbial resistance. Numerous worldwide clinical studies have shown that 
PDT represents an effective and safe modality for various types of diseases [4-9], 
including osteomyelitis [10-12]. 
2. Mechanisms and drug development in PDT 
The cell killing mechanism of PDT is based on the process called photosensitization (Figure 
1), which involves a molecule that absorbs light and gets excited from the ground-state (PS) 
into singlet excited state (1PS*), which is short-lived (  10-9 seconds) and can be quickly 
deactivated by radiative and non-radiave processes before it has time to react. A good 
photosensitizer (PS) will undergo a photophysical process called intersystem crossing, 
which converts the singlet state to a triplet state (3PS1). Triplet states cannot relax efficiently 
having a higher tendency to donate or accept electrons, being therefore both stronger 
reducing and oxidant agents compared to the ground state. Triplets also have a large 
tendency to engage in energy transfer reactions especially with oxygen. When triplet states 
are disabled by electron transfer reactions, it originates radical species, in mechanisms that 
are called type I. These radicals can initiate radical chain reactions leading to damage in 
lipids, proteins and nucleic acids. In oxygenated environments the photosensitizers can 
undergo type II photochemical process that involves energy transfer between the excited 
triplet state of the photosensitizer and stable triplet oxygen (3O2), producing short lived and 
highly reactive singlet oxygen (1O2) [15-17]. 
Therefore, one can separate the mechanisms of PDT in two classes. The mechanism TYPE I: 
light energy passes from triplet excited molecules to biomolecules by electron transfer 
reactions (radical mechanism) that culminates in direct damage to biomolecules or the 
formation of reactive oxygen species. TYPE II mechanism in the excitation energy is 
transferred to molecular oxygen, resulting in the formation of singlet oxygen (1O2), which is 
highly electrophilic and capable of causing damage to membranes, proteins and DNA [16-
18]. The actual chemical mechanism that takes place in cells will depend on the specific 
microenvironment of the photosensitizer, and clearly depend on specific interactions with 
membranes and proteins [18-24]. Although most photosensitizer can bind DNA and can 
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Fig. 1. Photosensitization mechanisms where PS is a photosensitizer that absorbs light going 
to the first singlet state (1PS*), converting into a triplet state (3PS*) by intersystem crossing. 
The excited species, specially 3PS* can react by electron transfer forming radical species 
(Type I mechanism) and starting radical chain reactions or react with oxygen by energy 
transfer forming Singlet oxygen (Type II mechanism). 
photo-damage it in in-vitro solution-based experiments, the charged photosensitizers in use 
do not enter and do not accumulate in cell nuclei, decreasing the possibility of mutagenesis. 
Adjuvants like hydrogen peroxide can increase the photodynamic efficiency by allowing 
better uptake of the photosensitizer [25]. Also, nanoparticle platforms have a great potential 
to control the mechanisms and efficiency of photodynamic action [26-30].  
Penetration of light through the skin is dependent on the characteristics of the treated tissue, 
the absorption by endogenous chromospheres and the scattering of the skin tissues. 
Wavelengths shorter than 600 nm are absorbed mainly by hemoglobin and other skin 
choromophores, whereas vibration overtones of water and other molecules induce 
absorption at wavelengths longer than 950 nm. Tissue scattering, which decreases as the 
wavelength increases, hinders light penetration of shorter wavelength photons. Forward 
directed scattering allows for penetration even in high absorbing and scattering tissues. By 
considering all these processes one can explain light penetration depth (10-20 mm) inside 
the tissue in the therapeutic window, which is light wavelength from 600 to 950 nm [16]. 
Therefore, one should choose a photosensitizer that absorbs in the therapeutic window in 
order to treat internal tissues by PDT.  The light dose, which is usually given in joules per 
square centimeter, is empirical and varies widely. For interstitial applications, radiant 
exposures between 20 and 300 J/cm2 are needed [5-10, 16]. 
As mentioned above the first report of PDT action was of a dye (Acridine), which was used 
to kill a microorganism (paramecium) under illumination [15, 31]. Just few years after the 
experiment of Raab, the photodynamic concept was applied to dermatology using another 
dye (eosin) [31]. In 1912 Friedrich Betz Meyer published results of an experiment he did on 
himself, by injecting himself with a mixture of porphyrin oligomers and showed that he 
only had erythema reaction in tissues that were illuminated with light, proving that the 
photodynamic effect depends on light and on photosensitizer [31, 32].  
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In the 70´s-80´s the protocols developed by Dougherty and his group used a photosensitizer 
similar to the one Meyer injected himself with, which was called hematoporphyrin 
derivative (HPD, later called PhotofrinR, Figure 2D). HPD showed great potential to treat 
tumors, leading to the PDT approval by FDA as a treating modality for head and neck 
cancers [5, 33]. The protocols developed by Dougherty´s group rely on expensive laser 
systems, being restricted to only very few research centers in the world.  PhotofrinR targets 
mainly the leakage vasculature of tumor tissues [33, 34]. Intracellular photosensitizers were 
subsequently tested clinically and have shown to be potentially more efficient. Oseroff and 
co-workers were the first to propose the strategy of targeting intracellular organelles instead 
of the tumor vasculature [35].  
In the clinical realm, new generation photosensitizers were designed to have intracellular 
targets. A successful example was Foscan (Tetra-meso hydroxyphenyl chlorin, Figure 2F), 
which is a powerful intra-cellular photosensitizer. Its high photodynamic efficiency has been 
explained by the photooxidation of intracellular targets, because the quantum yields of 
singlet oxygen production is comparable or inferior to other relevant photosensitizers [36, 
37].  The intracellular generation of protoporphyrin IX by administration of its metabolic 
precursors (ALA), was another successful example that helped to expand the applications of 
PDT (Figure 2E). Today almost any dermatologist around the world knows and uses PDT 
with ALA to treat a variety of skin diseases.  
It is important to mention that although being more efficient than the initial protocols, the 
available PDT treatments are still very expensive and consequently are nor very useful in 
terms of public health, especially for developing and under-developed countries. In fact, 
during three decades of clinical PDT, most of the treating protocols were based on the use of 
hematoporphyrin and its derivatives, irradiated with lasers or very sophisticated non-
coherent light sources [5,16]. The combination of inexpensive photosensitizers and light 
sources have allowed the development of new PDT protocol that are inexpensive, safe and 
efficient [6-10]. Therefore, we can conclude that there is a great potential for the widespread 
use of PDT even in underserved populations. 
The concept of photodynamic cell killing was soon extended to treat infectious diseases, i.e., 
its photoantimicrobial action [4, 38]. The effect of the generation of large amounts of radicals 
and non-radicals oxidizing species on microbials is extremely destructive for two main 
reasons: lack of effective microbial defenses against these species and multiple sites of 
attack. Although cells have several natural defenses against reactive species, the level of 
redox imbalance inflicted by PDT is several orders of magnitude larger than the level or 
protection allowed by enzymatic and molecular antioxidants within the cell. Besides that, 
bacteria can defend itself against superoxide radical and hydrogen peroxide, but hydroxyl 
radical and singlet oxygen cannot be naturally deactivated. Consequently, an important 
advantage of PDT is the absence of microbial resistance [4, 38].  
The development of improved drugs in any pharmaceutical application depends on the 
knowledge of structure activity-relationships and of the action mechanisms involved. We 
and others have invested a lot of efforts on solving these issues related with PDT [6,16-25]. 
New molecular structures, nanoparticles or nanoemulsions are being investigated in order 
to develop new and more efficient photo-active drugs [18-30]. Several medical conditions 
were treated by different protocols and depending on the medical condition, specific 
molecules and delivery systems were designed [5-10]. There are several low-cost options to  
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Fig. 2. Examples of photosensitizers used in PDT, from A to E, hypericin, methylene blue, 
crystal violet, hematoporphyrin derivative and tetra-meso-hydroxyphenyl-chlorin 
(FoscanR).  Compound labeled F is 5-aminolevulinic acid (ALA), which is a pro-drug that is 
metabolized in the intra-cellular environment to the actual photosensitizer that is 
Protoporphyrin IX. 
be considered as photosensitizers in PDT, which include hypericin, methylene blue and 
other phenothiazines, crystal violet and other tryarilmethanes (Figure 2A-C). 
3. PDT in the case of osteomyelitis 
The classical treatment of osteomyelitis requires surgical removal of the diseased tissue and 
high doses of antibiotics, which are often nephrotoxic, further compromising the health of 
patients. In-vitro and animal studies in the laboratory have shown the potential of PDT for 
causing efficient cell death of infecting bacteria as well as treating animals with the disease 
[11,12].  Low-cost PDT protocols were also tested with success in diabetic patients with 
osteomyelitis [10]. 
A B 
C D 
F E 
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Fig. 3. Two osteomyelitis patients that were selected in the clinical studies conducted by JP 
Tardivo in the Hospital da Fundação ABC. The picture in the left shows how Methylene 
Blue solution is injected in the bone through the fistula. In the right the illumination with 
optical fiber conducted by the continuous white-light source (FASA). 
 
Fig. 4. Plantar region of the thumb of a diabetic patient with osteomyelitis pre and post 
treatment with PDT. A 1:1 mixture of MB 2% and TB 2% was injected into the patient’s great 
toe. Further details of treatment and conditions are described in Reference 10.  
PDT in osteomyelitis is intended to eliminate any micro-organism that is installed in bone 
tissue. In order to combat infection in the bone and soft tissue a photosensitizer solution has 
to be introduced in the lesion tissue that must be subsequently illuminated (Figures 3, 4). 
Usually this can be easily realized by administrating the photosensitizer by the drainage of 
the skin fistulas, which reaches the bone (Figure 3). Illumination should be conducted for 
around 10 minutes to allow a light dose of around ~20-30 J/cm2, by internal and external 
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irradiation. Internal irradiation is obtained by introducing optical fibers delivering light 
directly in the bone and external irradiation with non-coherent polychromatic light sources 
(Figures 3 and 4). Patients are only accompanied in the ambulatory throughout the 
treatment, which usually lasts for several weeks. In that period, spontaneously removal of 
bone fragments was observed by radiographies, fistulas were healed and patient were 
considered cured (Figures 3 and 4). In the clinical studies conducted so far, 12 patients were 
treated with success and 8 are being treated. The patients selected in this clinical study had 
not responded well to usual antibiotic therapy and had had indication of amputation. 
 
Fig. 5. Radiography of great toe of P1 before (A) and after (B) PACT treatment. Arrows in A: 
fractures in distal and proximal phalanges. Arrows in B: bone fragments spontaneously 
removed after treatment. A 1:1 mixture of MB 2% and TB 2% was injected into the patient’s 
great toe. Further details of treatment and conditions are described in Reference 10. 
4. Conclusions 
Photodynamic therapy reduces the risk of amputation, causing cell death to microorganisms 
that are infecting bone tissues and consequently accelerate healing of osteomyelitis lesions. 
It also reduces inflammation and pain in the tissue ulcers. PDT provides an efficient and 
quick treatment that helps avoiding amputations. The physiological/cosmetic outcomes are 
impressive with small side effects (small pain during treatment is sometimes reported). 
Besides all these benefits, PDT may be performed in office or clinic and low-cost protocols 
are available. Consequently, PDT can clearly help to improve the quality of life of diabetic 
patients. 
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